Back to dashboard
CommercialCoverageLow impact

08.02.14a, Casgevy™ (exagamglogene autotemcel)

Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Dec 19, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Independence Blue Cross has reissued their policy for Casgevy™ (exagamglogene autotemcel), a gene therapy medication. This is a pharmacy policy update that will take effect December 19, 2025, affecting coverage and billing requirements for this specialized treatment.

Action Required

Action needed
By December 19, 2025: Review updated Casgevy™ policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for this gene therapy. Contact Independence Blue Cross directly for specific billing code requirements and coverage details not available in the summary.

Related policy hubs